The hypothesis to be tested in this project is that activation of ATM, phosphatidylinositol-3 kinase (PI-3 kinase), epidermal growth factor receptor (EGFR), MAP kinase JNKs and p38 kinases play a functional role in UVB induced signal transduction and skin carcinogenesis. Therefore these signaling molecules can be used as targets for the development of chemopreventive agents to inhibit UV/k-induced non-melanoma skin cancers. The agents of interest include PI-3 kinase inhibitors (LY294002 and inositol hexaphosphate), EGFR inhibitors (PD153035 and AG1478), JNKs inhibitor SP600125 and p38 kinase inhibitor SB202190.
The Specific Aims to address the hypothesis are to: (1) Determine whether UVA-induced apoptosis is mediated by activation of an ATM-dependent p53 pathway in human and mouse keratinocytes. (2) Determine whether genetic knockout of Jnkl and Jnk2 in mice inhibits UVA-induced skin carcinogenesis. (3) Determine whether targeted expression of a mutant p85 subunit of phosphatidylinositol-3 (PI-3) kinase or a dominant negative p38 kinase (DNp38) in the epidermis of transgenic mice inhibits UVA-induced skin carcinogenesis. (4) Utilize known inhibitors of p38 and JNK MAP kinases, EGFR, ATM and PI-3 kinases targeted to the skin to determine whether these effective inhibitors will prevent UVA-induced skin carcinogenesis in an SKH-1 hairless mouse model. (5) To cross validate the targets for chemoprevention between mouse and human models of UVA skin carcinogenesis. This project will focus on UVA-induced carcinogenesis and chemoprevention strategies, and will closely interact with Project 1, which will focus on UVB-induced carcinogenesis and chemoprevention strategies. These preclinical studies are designed to lead to the development of new strategies for the chemoprevention of human skin cancers, which will be tested in Project 4.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA027502-23A1
Application #
6991757
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
23
Fiscal Year
2004
Total Cost
$293,917
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278
Knights-Mitchell, Shellie S; Romanowski, Marek (2018) Near-Infrared Activated Release of Doxorubicin from Plasmon Resonant Liposomes. Nanotheranostics 2:295-305
Roh, Eunmiri; Lee, Mee-Hyun; Zykova, Tatyana A et al. (2018) Targeting PRPK and TOPK for skin cancer prevention and therapy. Oncogene 37:5633-5647
Chen, Yin; Vasquez, Monica M; Zhu, Lingxiang et al. (2017) Effects of Retinoids on Augmentation of Club Cell Secretory Protein. Am J Respir Crit Care Med 196:928-931
Yamamoto, Hiroyuki; Ryu, Joohyun; Min, Eli et al. (2017) TRAF1 Is Critical for DMBA/Solar UVR-Induced Skin Carcinogenesis. J Invest Dermatol 137:1322-1332
Zykova, Tatyana A; Zhu, Feng; Wang, Lei et al. (2017) The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis. EBioMedicine 18:73-82
Einspahr, Janine G; Curiel-Lewandrowski, Clara; Calvert, Valerie S et al. (2017) Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light. NPJ Precis Oncol 1:
Gao, Ge; Zhang, Tianshun; Wang, Qiushi et al. (2017) ADA-07 Suppresses Solar Ultraviolet-Induced Skin Carcinogenesis by Directly Inhibiting TOPK. Mol Cancer Ther 16:1843-1854
Janda, Jaroslav; Burkett, Nichole B; Blohm-Mangone, Karen et al. (2016) Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-?B and AP-1 Signaling in Keratinocytes and Mouse Skin. Photochem Photobiol 92:816-825
Peng, C; Zeng, W; Su, J et al. (2016) Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway. Oncogene 35:1170-9

Showing the most recent 10 out of 395 publications